| |
Financial Year 2009 - 2010
Quarter I
(June 2009)
Financial Year 2008 - 2009
Quarter IV
(March 2009)
Quarter III
(December 2008)
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED
31st DECEMBER 2008
| (Rs. in Lakhs) |
| Sl. No |
Particulars |
Quarter ended 31st December |
Nine months ended 31st December |
Year ended
31st March 2008
(Audited) |
| 2008 (Un Audited) |
2007 (Un Audited) |
2008 (Un Audited) |
2007 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
|
a) Net Sales / Income from
Operations
- Sales (net)
b) Other Operating Income
- Other Income from Operations
- Income from Potential
patent infringement suit
Total
Expenditure
a) (Increase) / Decrease in
Stock trade and work
in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee cost
e) Depreciation
& Amortization (excluding R & D)
f)Other Expenditure
Total
Profit from operations
before other income,
interest, exceptional items
and R&D (1-2)
Research and Development
Expenditure
Interest
Profit from Operations
before Other Income,
Interest & Exceptional
Items (3-4)
Other income
Profit before Interest &
Exceptional Items (5+6)
Interest and Finance Cost
Profit after Interest but
before Exceptional
Items (7-8)
Provision for impairment of
goodwill
Profit / (Loss) before tax
and after exceptional
item (9-10)
Tax expense
Profit / (Loss) after Tax but
before Minority Interest
and share in Associate
(11-12)
Less : Minority Interest
share of Profit / Loss
Less : Share of Loss
in Associate
Net Profit / (Loss) after
Tax (13-14-15)
Paid-up equity share capital (Face value - Rs.2 each)
Reserves excluding revaluation
reserves
Earning Per Share (Not
annualised) - (Face Value
- Rs.2 each)
On Profit / (Loss) after Tax :
- Before Exceptional Item
- Basic ( Rs )
- Diluted ( Rs )
- After Exceptional Item
- Basic ( Rs )
- Diluted ( Rs )
|
58,065
99
-
58,164
1,126
21,163
8,619
6,270
1,783
11,142
50,103
8,061
5,330
2,731
467
3,198
4,104
(906)
-
(906)
2,244
(3,150)
169
27
3,292
3,092
-
2.13
2.13
2.13
2.13
|
44,494
184
677
45,355
(4,168)
18,831
7,146
5,315
1,182
8,166
37,102
8,253
3,420
4,883
589
5,422
2,675
2,747
-
2,747
1,301
1,446
70
29
1,545
3,092
-
1.00
1.00
1.00
1.00
|
1,62,825
322
1,346
1,64,493
(4,295)
60,951
26,197
17,811
5,051
29,580
1,35,295
29,198
16,202
12,996
2,050
15,046
11,107
3,939
-
3,939
5,630
(1,691)
(239)
(101)
(2,031)
3,092
-
1.31
1.31
1.31
1.31
|
1,26,836
503
2,022
1,29,361
(3,840)
47,131
22,560
13,980
4,798
23,282
1,07,911
21,450
9,815
11,635
1,973
13,608
7,106
6,502
-
6,502
3,629
2,873
392
(26)
3,239
3,092
-
2.10
2.09
2.10
2.09
|
1,72,807
661
2,691
1,76,159
(8,168)
66,012
32,201
18,825
6,055
31,894
1,46,819
29,340
14,233
15,107
2,447
17,554
9,654
7,900
48,712
(40,812)
5,297
(46,109)
419
(3)
(45,693)
3,092
65,388
1.96
1.95
(29.59)
(29.59)
|
Segment Information:
Net Segment Revenue:
-Pharmaceuticals
-Medical Supplies
Total
Segment Results :
Profit before tax and interest
from each segment
-Pharmaceuticals
-Medical Supplies
Total
Less: Interest & Finance cost
Total Profit / Loss before tax and
Exceptional Items
Capital Employed :
-Pharmaceuticals
-Medical Supplies
-Unallocated
Total
|
52,819
5,246
58,065
3,091
107
3,198
(4,104)
(906)
1,81,550
5,722
86,138
2,73,410
|
40,409
4,085
44,494
5,189
233
5,422
(2,675)
2,747
1,42,067
4,327
1,19,570
2,65,964
|
1,48,018
14,807
1,62,825
14,148
898
15,046
(11,107)
3,939
1,81,550
5,722
86,138
2,73,410
|
1,15,420
11,416
1,26,836
13,098
510
13,608
(7,106)
6,502
1,42,067
4,327
1,19,570
2,65,964
|
1,57,067
15,740
1,72,807
16,983
571
17,554
(9,654)
7,900
1,56,740
4,825
79,771
2,41,336
|
|
| Notes : |
The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 28th January 2009. The figures for the previous year / period have been rearranged/regrouped wherever necessary to conform to current period's presentation. "On 14th January, 2009, the Board of Directors of Matrix Laboratories Limited (“Matrix”) approved assignment to its parent company, MP Laboratories (Mauritius) Ltd
(“MP Laboratories”), a wholly-owned subsidiary of Mylan Inc., USA, purchase rights, to acquire from Aspen Pharmacare Holdings Ltd (“Aspen”), South Africa, a portion of the shareholding of Astrix Laboratories Ltd (“Astrix”). Pursuant to this assignment, MP Laboratories will purchase 49% of share capital of Astrix while Matrix will purchase the remaining 1%, thereby consolidating its holding to 51%."
|
| |
For and on behalf of the Board
|
Place : Warsaw
Date : 28th January 2009 |
S. Srinivasan
Managing Director & Chief Executive Officer
|
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
31st DECEMBER 2008
| (Rs. in Lakhs ) |
| Sl. No |
Particulars |
Quarter ended 31st December |
Nine months ended 31st December |
Year ended
31st March 2008
(Audited) |
| 2008 (Un Audited) |
2007 (Un Audited) |
2008 (Un Audited) |
2007 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
| Net Sales / Income from Operation
-Exports
-Domestic
b) Other Operating Income
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Expenditure
a) Increase in Stock in trade and work in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee cost
e) Depreciation & Amortization
(excluding R & D)
f) Other Expenditure
Total
Profit from Operations
before Other Income,
Interest, Exceptional Items
and R&D (1-2)
Research and Development
Expenditure(including
depreciation)
Profit from Operations
before Other Income,
Interest & Exceptional
Items (3-4)
Other Income
Profit before Interest
& Exceptional Items (5+6)
Interest and Finance Cost
Profit after Interest but
before Exceptional
Items (7-8)
Provision for diminution in
the value of investment
in subsidiary
Profit/(Loss) before tax
and after exceptional
item (9-10)
Tax expense
Net Profit/(Loss) after
tax (11-12)
Paid-up equity share capital
(Face value - Rs.2/- each)
Reserves excluding
revaluation reserves
Earning Per Share (EPS) Not
annualised) On Profit / (Loss)
after Tax :
Before Exceptional Item
- Basic
- Diluted
After Exceptional Item
- Basic
- Diluted
Public Share holding
- Number of shares
- Percentage of share holding
|
33,983
5,432
198
-
39,613
(854)
20,483
704
2,352
908
5,576
29,169
10,444
4,183
6,261
687
6,948
1,604
5,344
-
5,344
1,730
3,614
3,092
-
2.34
2.34
2.34
2.34
3,69,10,189
23.87%
|
17,110
9,148
368
676
27,572
(2,784)
15,748
4
1,877
741
4,181
19,767
7,805
2,895
4,910
383
5,293
835
4,458
-
4,458
1,024
3,434
3,092
-
2.23
2.22
2.23
2.22
3,68,76,696
23.85%
|
86,277
17,327
643
1,346
1,05,593
(6,947)
55,332
1,345
6,935
2,607
14,808
74,080
31,513
13,151
18,362
1,788
20,150
4,000
16,150
-
16,150
4,333
11,817
3,092
-
7.64
7.64
7.64
7.64
3,69,10,189
23.87%
|
42,357
24,986
1,006
2,022
70,371
(4,106)
37,918
17
5,324
2,199
11,471
52,823
17,548
7,407
10,141
1,544
11,685
1,871
9,814
-
9,814
2,436
7,378
3,092
-
4.78
4.76
4.78
4.76
3,68,76,696
23.85%
|
62,066
31,797
1,322
2,691
97,876
(7,258)
53,412
354
7,038
2,954
15,896
72,396
25,480
10,641
14,839
2,018
16,857
2,727
14,130
40,118
(25,988)
3,848
(29,836)
3,092
64,899
6.66
6.64
(19.32)
(19.32)
3,68,76,696
23.85%
|
|
| Notes : |
- The above results were subjected to a limited review by the auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 28th January 2009.
- The activities of the Company relate to only one reportable segment i.e. Pharmaceuticals.
- Tax expense includes Current tax Rs.937 lakhs (Quarter ended 31st December 2007 Rs.505 lakhs), adjustment relating to past years of Rs.152 lakhs (Quarter ended 31st December 2007 Rs.Nil ), Deferred Tax Rs.521 lakhs (Quarter ended 31st December 2007 Rs.916 lakhs) and Fringe benefit tax Rs.33 lakhs (Quarter ended 31st December 2007 Rs.55 lakhs) and is net of MAT credit available of Rs.(87) lakhs (Quarter ended 31st December 2007 Rs.452 lakhs).
- The figures for the previous year / period have been rearranged/regrouped wherever necessary to conform to current period's presentation.
- Summary of Investor Complaints :
Opening : Nil, Received during the quarter : 4, Resolved : 4, Closing : Nil.
- The Board of Directors at their meeting held on 29th October, 2008 approved conversion of 6718 partly paid up Equity Shares of Rs.2/-each into fully paid up shares.
- "On 14th January, 2009, the Board of Directors of Matrix Laboratories Limited (“Matrix”) approved assignment to its parent company, MP Laboratories (Mauritius) Ltd (“MP Laboratories”), a wholly-owned subsidiary of Mylan Inc., USA, purchase rights, to acquire from Aspen Pharmacare Holdings Ltd (“Aspen”), South Africa, a portion of the share holding of Astrix Laboratories Ltd (“Astrix”). Pursuant to this assignment, MP Laboratories will purchase 49% of share capital of Astrix while Matrix will purchase the remaining 1%, thereby consolidating its holding to 51%.
|
| |
For and on behalf of the Board
|
Place : Warsaw
Date : 28th January 2009 |
S.Srinivasan
Managing Director & Chief Executive Officer
|
|
|
